Sign in
Taking people in United StatesPhase 3

JNJ-101556143 for Advanced Prostate Cancer That No Longer Responds to Hormone Treatments

Tests JNJ-101556143 plus supportive care in men with hormone-resistant metastatic prostate cancer.

Key facts

Who runs it
Janssen Research & Development, LLC
Where
El Paso, Murray, and The Woodlands, United StatesSee the 3 sitesAlso in 1 other country, 1 site
Registry title
A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer
Status
Recruiting
Phase
Phase 3
People taking part
400 people, planned
Started
29 Oct 2026
Expected to end
18 Aug 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • JNJ-101556143
  • Placebo
  • Best Supportive Care
Record updated
3 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with prostate cancer that has spread and no longer responds to hormone treatments. It tests JNJ-101556143 with supportive care against placebo with supportive care.

Age
18 years or older.
Sex
Men only.
Disease stage
Prostate adenocarcinoma that has spread and keeps getting worse despite hormone treatment. PSA level of at least 10 ng/mL, plus rising PSA or worsening disease or new lesions on scans.
Earlier treatment
Must have had all life-prolonging treatments they can have and can access. Must be on ongoing testosterone-lowering treatment (surgery or medication), with testosterone below 50 ng/dL or 1.7 nmol/L. Other cancer treatments must have stopped 2 weeks before (4 weeks for 177Lu PSMA-617).
Biomarker or test result
PSA of at least 10 ng/mL; testosterone below 50 ng/dL (1.7 nmol/L).

Main reasons for not taking part

  • Small cell, carcinoid, neuroendocrine or sarcoma type of prostate cancer
  • Uncontrolled kidney disease, pancreatitis or liver disease
  • Allergy to JNJ-101556143 or its ingredients
  • Major surgery or serious injury within 28 days of the first dose
  • Spinal cord compression without finished treatment and 28 stable days

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Have histologically confirmed adenocarcinoma of the prostate. Primary (or pathologic evidence of conversion to) small cell carcinoma, carcinoid tumor, mixed neuroendocrine carcinoma, large cell neuroendocrine carcinoma, or sarcoma of the prostate is disallowed
  • Progressive metastatic androgen pathway modulation-resistant prostate cancer (mAPMR) defined as having a Prostate-Specific Antigen (PSA) level greater than or equal (>=) 10 nanograms per milliliter (ng/mL) and at least one of the following: (a) PSA progression defined as at least 2 consecutive increases in PSA value over a previous reference value measured at least 1 week apart. (b) Progressive disease or new lesion(s) in the lymph nodes, bones, or viscera on conventional imaging (computed tomography [CT]/magnetic resonance imaging [MRI]) as defined by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) and/or on bone scan per Prostate Cancer Working Group 4 (PCWG4) while on Androgen Deprivation Therapy (ADT) (either surgically [bilateral orchiectomy] or with medication)
  • Participants should have had all life-prolonging therapies for which they are clinically eligible in the opinion of the investigator and to which they have access
  • Prior bilateral orchiectomy or medical castration (receiving ongoing ADT with a Gonadotropin-Releasing Hormone (GnRH) analog [agonist or antagonist]) with castrate level of serum testosterone (less than [<] 50 nanograms per deciliter [ng/dL] or 1.7 nanomoles per liter [nmol/L]) prior to the first dose of trial intervention and must continue this therapy throughout the treatment phase
  • Have discontinued concurrent use of any non-investigational systemic anticancer therapy (that is, cytotoxic chemotherapy, Androgen Receptor Pathway Inhibitor (ARPI), radiation therapy) non-sponsor investigational drugs within 2 weeks or Lutetium-177 Prostate-Specific Membrane Antigen-617 (177\^Lu PSMA-617) within 4 weeks prior to randomization and may not have participated in an investigational trial within the sponsor's development program within 6 months prior to randomization
  • Toxicity related to prior anticancer treatment that is deemed clinically relevant must have resolved to common terminology criteria for adverse events (CTCAE) Version 6.0 Grade 1 or better

Who cannot take part

  • Had major surgery or had significant traumatic injury less than or equal to 28 days of the first dose of trial intervention
  • Spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days
  • Solid organ or bone marrow transplantation
  • Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease (with exception of patients with Gilbert's Syndrome, asymptomatic gallstones, liver metastases, or stable chronic liver disease per investigator assessment)
  • Suspected or known allergies, hypersensitivity, or intolerance to JNJ-101556143 or its excipients

Where in United States

Also in 1 other country, 1 site

  • Renovatio Clinical 1El Paso, United StatesTaking people
  • Summit Urology Folio Clinical ResearchMurray, United StatesTaking people
  • Renovatio ClinicalThe Woodlands, United StatesTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate how well JNJ-101556143 plus Best Supportive Care (BSC) improves overall survival (the length of time a participant remains alive) compared with placebo plus BSC in participants with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR). mAPMR is an advanced form of prostate cancer that has spread to other parts of the body and no longer responds to hormone treatments designed to block male hormones (androgens).

The 2 groups in the trial

  • JNJ-101556143 + Best Supportive CareTreatment being tested

    Participants will receive JNJ-101556143 orally once daily along with Best Supportive Care. Treatment will continue until discontinuation criteria are met.

    Treatment: JNJ-101556143 and Best Supportive Care

  • Placebo + Best Supportive CarePlacebo, for comparison

    Participants will receive matching placebo orally once daily along with Best Supportive Care. Treatment will continue until discontinuation criteria are met.

    Treatment: Placebo and Best Supportive Care

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of JNJ-101556143, a Regulated Induced Proximity Targeting Chimera (RIPTAC™) Therapeutic Plus Best Supportive Care Versus Best Supportive Care in Participants With Metastatic Androgen Pathway Modulation-Resistant Prostate Cancer
Plain-language title
JNJ-101556143 for Advanced Prostate Cancer That No Longer Responds to Hormone TreatmentsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
3 November 2026